Skip to main content
Bliss GVS Pharma Limited logo

Bliss GVS Pharma Limited — Investor Relations & Filings

Ticker · BLISSGVS ISIN · INE416D01022 LEI · 335800GXY3YCGGP7KJ45 BSE.NS Manufacturing
Open in API
Filings indexed 1,245 across all filing types
Latest filing 2021-07-31 Board/Management Inform…
Country IN India
Listing BSE.NS BLISSGVS

About Bliss GVS Pharma Limited

https://blissgvs.com/

Bliss GVS Pharma Limited specializes in the development, manufacturing, and marketing of diverse pharmaceutical formulations. The company is a global leader in the production of suppositories and pessaries, maintaining an extensive portfolio within these specialized dosage forms. Its therapeutic focus includes anti-malarials, anti-fungals, anti-bacterials, anti-inflammatories, and gastrointestinal treatments. The organization operates state-of-the-art manufacturing facilities compliant with international quality standards, including WHO-GMP. With a strategic focus on emerging markets, the company distributes its range of prescription and over-the-counter products across Sub-Saharan Africa, Southeast Asia, and Latin America, leveraging a robust supply chain to provide accessible healthcare solutions.

Recent filings

Filing Released Lang Actions
Appointment
Board/Management Information Classification · 95% confidence The document is a detailed announcement of the outcome of a Board Meeting held on July 31, 2021. It includes approval of unaudited standalone and consolidated financial results for the quarter ended June 30, 2021, re-appointments of whole-time directors, constitution of a Risk Management Committee, adoption of a Dividend Distribution Policy, and scheduling of the 36th Annual General Meeting. The document contains specific board decisions and profiles of directors being re-appointed. It is not the full financial report itself but an official disclosure of board meeting outcomes including financial results and management changes. This fits the category of Board/Management Information (MANG) as it announces board decisions and management appointments. The document length (11,187 characters) and content confirm it is not a brief announcement or a full annual/interim report but a comprehensive board meeting outcome disclosure.
2021-07-31 English
Outcome of Board Meeting
Interim / Quarterly Report Classification · 95% confidence The document is a detailed announcement from Bliss GVS Pharma Ltd. regarding the outcome of a Board Meeting held on July 31, 2021. It includes approval of unaudited standalone and consolidated financial results for the quarter ended June 30, 2021, re-appointments of whole-time directors, constitution of a Risk Management Committee, adoption of a Dividend Distribution Policy, and scheduling of the 36th Annual General Meeting. The document contains actual financial data including revenue, expenses, profit, and tax details for the quarter ended June 30, 2021, which indicates it is a financial report rather than a mere announcement. The presence of unaudited financial results for a quarter strongly suggests this is an Interim / Quarterly Report. It is not a full Annual Report (10-K) as it covers a quarter, not a full fiscal year. It is not a simple announcement or certification, but contains substantive financial data and analysis. Therefore, the appropriate classification is Interim / Quarterly Report (IR).
2021-07-31 English
Dear Sir/Madam, Pursuant to Section 91 of the Companies Act, 2013 ('Act'') and applicable Regulations of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ....
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to the stock exchange's listing department, notifying about the book closure dates for the purpose of the 36th Annual General Meeting (AGM) and payment of the final dividend for the financial year ended March 31, 2021. It references compliance with SEBI Listing Regulations and the Companies Act, 2013. The document is short (3190 characters) and serves as an announcement of the book closure and AGM date rather than the AGM materials themselves. It does not contain financial statements or detailed AGM presentations. Therefore, it is best classified as a Regulatory Filing (RNS) since it is a regulatory announcement related to corporate actions but not the AGM information or dividend notice itself.
2021-07-31 English
Re-appointment of M/s. AVS & Associates, Practicing Company Secretaries as Secretarial Auditor of the Company for the financial year 2021-2022.
Regulatory Filings Classification · 95% confidence The document is an official announcement from Bliss GVS Pharma Ltd. regarding the outcome of a Board Meeting held on July 31, 2021. It includes approval of unaudited standalone and consolidated financial results for the quarter ended June 30, 2021, re-appointments of whole-time directors, re-appointment of secretarial auditor, constitution of a Risk Management Committee, adoption of Dividend Distribution Policy, and scheduling of the 36th Annual General Meeting. The document is primarily an announcement of decisions made at the Board Meeting rather than the full financial report itself. It contains no detailed financial statements or substantive financial data but references the financial results and includes limited review reports as annexures. Therefore, it is best classified as a Regulatory Filing (RNS) as it is a general regulatory announcement about board decisions and financial results approval, not the full quarterly report or earnings release.
2021-07-31 English
1) Re-appointment of Mrs. Shruti Vishal Rao (DIN: 00731501) as Whole-Time Director of the Company for another period of three years with effect from April 01, 2022 to March 31, 2025. ....
Board/Management Information Classification · 95% confidence The document is a detailed announcement of the outcome of a Board Meeting held on July 31, 2021. It includes approval of unaudited standalone and consolidated financial results for the quarter ended June 30, 2021, re-appointments of Whole-Time Directors, constitution of a Risk Management Committee, adoption of Dividend Distribution Policy, and scheduling of the 36th Annual General Meeting. The document contains specific board decisions, director appointments, and committee formations, but it is not a full financial report or earnings release. It is a formal disclosure to stock exchanges as per SEBI regulations about board meeting outcomes and related corporate governance matters. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management and related board decisions. The document length (11,187 characters) and content confirm it is not a brief announcement or a report publication notice but a substantive board meeting outcome disclosure.
2021-07-31 English
Financial Result Updates
Interim / Quarterly Report Classification · 95% confidence The document is a detailed announcement from Bliss GVS Pharma Ltd. regarding the outcome of a Board Meeting held on July 31, 2021. It includes approval of unaudited standalone and consolidated financial results for the quarter ended June 30, 2021, re-appointments of whole-time directors, constitution of a Risk Management Committee, adoption of a Dividend Distribution Policy, and scheduling of the 36th Annual General Meeting. The document contains actual financial data including revenue, expenses, profit, and tax details for the quarter ended June 30, 2021, which indicates it is a comprehensive interim financial report rather than a brief announcement or a certification. The presence of unaudited financial results for a quarter strongly aligns with the definition of an Interim / Quarterly Report (IR). It is not merely an announcement of a report but contains substantive financial data and analysis. Therefore, the correct classification is Interim / Quarterly Report (IR).
2021-07-31 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.